• Wilson Roa, Lucyna Kepka, Narendra Kumar, Valery Sinaika, Juliana Matiello, Darejan Lomidze, Dalenda Hentati, Douglas Guedes de Castro, Katarzyna Dyttus-Cebulok, Suzanne Drodge, Sunita Ghosh, Branislav Jeremić, Eduardo Rosenblatt, and Elena Fidarova.
• Wilson Roa, Suzanne Drodge, and Sunita Ghosh, University of Alberta, Alberta Health Services-Cancer Control, Edmonton, Alberta, Canada; Lucyna Kepka, Warmia and Mazury Oncology Center, Olsztyn; Katarzyna Dyttus-Cebulok, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland; Narendra Kumar, Postgraduate Institute of Medical Education and Research, Chandigarh, India; Valery Sinaika, N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus; Juliana Matiello, Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Douglas Guedes de Castro, Castro DG, AC Camargo Cancer Center, São Paulo, Brazil; Darejan Lomidze, High Technology Medical Center, University Clinic, Tbilisi, Georgia; Dalenda Hentati, Institut National de Cancer Salah Azaiz, Ministère de la Santé Publique, Bab Saadoum, Tunisia; Branislav Jeremić, Institute of Lung Diseases, Institutski put 4, Sremska Kamenica, Serbia; and Eduardo Rosenblatt and Elena Fidarova, International Atomic Energy Agency, Vienna, Austria. wilson.roa@albertahealthservices.ca.
• J. Clin. Oncol. 2015 Dec 10; 33 (35): 4145-50.

PurposeThe optimal radiotherapy regimen for elderly and/or frail patients with newly diagnosed glioblastoma remains to be established. This study compared two radiotherapy regimens on the outcome of these patients.Patients And MethodsBetween 2010 and 2013, 98 patients (frail = age ≥ 50 years and Karnofsky performance status [KPS] of 50% to 70%; elderly and frail = age ≥ 65 years and KPS of 50% to 70%; elderly = age ≥ 65 years and KPS of 80% to 100%) were prospectively randomly assigned to two arms in a 1:1 ratio, stratified by age (< and ≥ 65 years old), KPS, and extent of surgical resection. Arm 1 received short-course radiotherapy (25 Gy in five daily fractions over 1 week), and arm 2 received commonly used radiotherapy (40 Gy in 15 daily fractions over 3 weeks).ResultsThe short-course radiotherapy was noninferior to commonly used radiotherapy. The median overall survival time was 7.9 months (95% CI, 6.3 to 9.6 months) in arm 1 and 6.4 months (95% CI, 5.1 to 7.6 months) in arm 2 (P = .988). Median progression-free survival time was 4.2 months (95% CI, 2.5 to 5.9) in arm 1 and 4.2 months (95% CI, 2.6 to 5.7) in arm B (P = .716). With a median follow-up time of 6.3 months, the quality of life between both arms at 4 weeks after treatment and 8 weeks after treatment was not different.ConclusionThere were no differences in overall survival time, progression-free survival time, and quality of life between patients receiving the two radiotherapy regimens. In view of the reduced treatment time, the short 1-week radiotherapy regimen may be recommended as a treatment option for elderly and/or frail patients with newly diagnosed glioblastoma.© 2015 by American Society of Clinical Oncology.

24 keywords...

hide…